Skip to main content
NCBI home page
Oncology Letters logoLink to Oncology Letters
. 2019 Mar 18;17(6):4985–4993. doi: 10.3892/ol.2019.10155

PAX3 is a biomarker and prognostic factor in melanoma: Database mining

Yong Liu 1,*, Shengnan Cui 2,*, Wenbin Li 1, Yiding Zhao 1, Xiaoning Yan 1,✉, Jianqin Xu 1,✉
PMCID: PMC6507366  PMID: 31186709

Abstract

Paired box 3 (PAX3) is a transcription factor and critical regulator of pigment cell development during embryonic development. However, while there have been several studies on PAX3, its expression patterns and precise role remain to be clarified. The present study is an in-depth computational study of tumor-associated gene information, with specific emphasis on the expression of PAX3 in melanoma, using Oncomine along with an investigation of corresponding expression profiles in an array of cancer cell lines through Cancer Cell Line Encyclopedia analysis. Based on Kaplan-Meier analysis, the prognostic value of high PAX3 expression in tissues from patients with melanoma compared with normal tissues was assessed. PAX3 was more highly expressed in male patients with melanoma compared with female patients with melanoma. Using Oncomine and Coexpedia analysis, it was demonstrated that PAX3 expression was clearly associated with SRY-box 10 expression. The survival analysis results revealed that high PAX3 mRNA expression was associated with worse survival rates in patients with melanoma. These results suggested that PAX3 may be a biomarker and essential prognostic factor for melanoma, and provided an important theoretical basis for the development of melanoma treatments.

Keywords: paired box 3, melanoma, database mining, prognostic value, biomarker

Introduction

Since the 1980s, the incidence of melanoma has been increasing at an annual rate of ~2.8% (1). Out of all patients diagnosed with cutaneous malignant melanoma, ~20% will succumb to metastatic disease, and the prognosis is significantly worse for those patients who are diagnosed with regional and distant metastases, with a 10-year survival rate of 64 and 16%, respectively (2,3).

Paired box 3 (PAX3) protein is known to be involved in the development of cancer (4). PAX3 protein contains two DNA binding domains; a paired domain and a homeodomain, which may function alone or in combination to bind downstream target genes (5–8).

Medic et al (9) suggested that the traditional developmental roles of PAX3 in regulating differentiation, proliferation, cell survival and migration are retained in melanoma cells. In melanoma, PAX3 expression is evident at all stages of disease progression, including primary lesions, circulating melanoma cells and metastatic lesions (10–14).

Previous studies have demonstrated that PAX3 can drive and activate C-X-C motif chemokine receptor 4 (CXCR4)/MET proto-oncogene receptor tyrosine kinase expression, and may promote melanoma metastasis and rapid tumor growth (15,16). E3 ligase APC/C (Cadherin 1) promotes ubiquitination-mediated PAX3 proteolysis and inhibits the proliferation of melanoma cells and melanoma growth (17). In addition, phosphorylation of PAX3 affects the melanoma phenotype (18). These findings may contribute to the further diagnosis, prognosis and potential treatment of melanoma.

In the present study, large databases of melanoma genetic information were analyzed to investigate the expression pattern of PAX3 in melanoma compared with normal tissues, and its association with characteristic molecular markers and their corresponding prognostic value in melanoma.

Materials and methods

Oncomine analysis

Oncomine (http://www.oncomine.org) is a gene chip-based database and integrated data mining platform in which conditions can be set for filtering and mining data. In the present study, the following screening conditions were used: i) Cancer type: Melanoma; ii) gene: PAX3; iii) data type: mRNA; iv) analysis type: Cancer vs. normal analysis; v) clinical outcome: Survival status; vi) outlier analysis: Overall survival follow-up time (days); and vii) threshold setting conditions (P<0.0001; fold change >2; gene rank <10%). The data output was saved in Excel format.

Cancer Cell Line Encyclopedia (CCLE) analysis

The mRNA expression levels of PAX3 and SRY-box 10 (SOX10) in various types of cancer were analyzed using CCLE (https://portals.broadinstitute.org/ccle/home), which is an online database of gene expression, chromosomal copy number and massively parallel sequencing data from 1,000 human cancer cell lines, aimed to facilitate the identification of genetic lineages and predictors of drug sensitivity.

Coexpedia analysis

Co-expression of PAX3 was analyzed using the Coexpedia database (http://www.coexpedia.org/), which is a database of context-associated co-expression networks inferred from individual series of microarray samples for human and mouse samples based on Gene Expression Omnibus data (https://www.ncbi.nlm.nih.gov/geo/). The generated network was a filtered network for the medical subject heading term ‘melanoma’. The score for each gene is a summation of edge-weights (Log likelihood score) to all connected genes in the network.

Statistical analysis

Differences in PAX3 expression between normal tissue and melanoma tissue were examined by unpaired t-test, and survival analysis for different groups was performed using the Kaplan-Meier method with log-rank test. The median of all sample expression values was calculated using descriptive statistical analyses. The data were expressed as the mean ± standard deviation. All data were analyzed using GraphPad Prism v7 software (GraphPad Software, Inc., La Jolla, CA, USA). P<0.05 was considered to indicate a statistically significant difference.

Results

Expression levels of PAX3 in all tumor types

A total of 439 different study results were analyzed in the Oncomine database (Fig. 1). Among them, there were nine studies with statistically significant differences in PAX3 expression, five studies with increased PAX3 expression and four with reduced PAX3 expression. In kidney cancer, there were two studies identifying increased expression and four studies identifying decreased expression. In melanoma, there were two studies identifying increased expression and no studies identifying decreased expression. Furthermore, the CCLE analysis was consistent with the Oncomine analysis, which indicates that the expression of PAX3 was increased in melanoma cell lines (Fig. 2).

Figure 1.

Figure 1.

Open in a new tab

mRNA expression pattern of paired box 3 in melanoma. Number of datasets with statistically significant mRNA overexpression (red) or downregulation (blue) of the target gene (cancer vs. normal tissue). The P-value threshold was set as 0.01. The number in each cell represents the number of analyses that met the threshold specific to a type of cancer. The gene rank was analyzed by percentile of the target gene in all genes measured in each study. Cell color is determined by the best gene rank percentile for the analyses within the cell. Melanoma is framed in red. CNS, central nervous system.

Figure 2.

Figure 2.

Open in a new tab

PAX3 is highly expressed in melanoma cell lines according to Cancer Cell Line Encyclopedia analysis. PAX3 mRNA expression was ranked highly in a variety of cancer cell lines (melanoma shown in green frame). The numbers in parentheses indicate the sample size and the y-axis number indicates mRNA expression (RNAseq). PAX3, paired box 3; AML, acute myeloid leukemia; B-cell_ALL, B-cell acute lymphocytic leukemia; CML, chronic myeloid leukemia; Lung_NSC, non-small cell lung cancer; Lymphoma_DLBCL, diffuse large B-cell lymphoma; NA, nasopharyngeal carcinoma; RNAseq, RNA sequencing; T-cell_ALL, T-cell acute lymphocytic leukemia.

Oncomine analysis revealed that in a dataset from Haqq et al (19), which included 25 melanoma, nine non-neoplastic nevus and three normal skin samples analyzed on cDNA microarrays, PAX3 mRNA expression in melanoma samples, including all subtypes, was increased 10.168-fold (P=3.92×10−5) and in non-neoplastic nevus it was increased 7.654-fold (P=1.08×10−5) compared with in normal tissues (Fig. 3A and B). In a dataset from Riker et al (20), which included 14 cutaneous melanoma and four normal skin samples analyzed on Affymetrix HG U133 Plus 2.0 microarrays, PAX3 expression in cutaneous melanoma samples was increased 3.902-fold (P=1.76×10−4) compared with in normal tissue (Fig. 3C). Additionally, in a study by Talantov et al (21), which included 45 cutaneous melanoma, 18 benign melanocytic skin nevus and seven normal skin samples analyzed on Affymetrix U133A microarrays, PAX3 mRNA expression in benign melanocytic skin nevus samples was increased 4.230-fold (P=0.003) and was increased 3.650-fold (P=0.005) in cutaneous melanoma samples compared with in normal tissues (Fig. 3D and E). These results suggested that PAX3 may serve a unique role in the development of melanoma.

Figure 3.

Figure 3.

Open in a new tab

Box plots derived from gene expression data in Oncomine comparing PAX3 mRNA expression in normal and melanoma tissue. The P-value was set at 0.01 and fold change was defined as 2. (A) Comparison of melanoma, including all subtypes and normal tissue (19). (B) Comparison of non-neoplastic nevus and normal tissue (19). (C) Comparison of cutaneous melanoma and normal tissue (20). (D) Comparison of benign melanocytic skin nevus and normal tissue (21). (E) Comparison of cutaneous melanoma and normal tissue (21). PAX3, paired box 3.

Co-expression analysis of PAX3

Since PAX3 was identified to be specific to melanoma, the potential role of PAX3 in melanoma was further investigated. In a dataset from Wagner et al (22), Coexpedia co-expression analysis suggested that SOX10 ranked first with a score of 2.778 (Table I and Fig. 4). In Oncomine co-expression analysis, and the dataset from Pratilas et al (23), PAX3 expression was identified to be significantly associated with SOX10 (r=0.806; Table II and Fig. 5). As shown in Tables I and II, co-expression analysis data indicated that PAX3 expression may be clearly associated with SOX10 expression. Additionally, similar results were obtained in the CCLE analysis, in which the mRNA expression level of SOX10 was ranked highest in melanoma cell lines (Fig. 6). In addition, SOX10 overexpression was observed in melanoma cell lines with high PAX3 expression, while low expression was observed in melanoma cell lines with low PAX3 expression (P=0.0017; Fig. 7). The aforementioned results suggested that SOX10 may be a co-expressed gene of PAX3.

Table I.

Co-expression analysis of PAX3 using Coexpedia.

Rank Gene Score
1 SOX10 2.778
2 PLP1 2.549
3 GYPC 2.498
4 EDNRB 2.489
5 S100B 2.457
6 C10orf90 2.377
7 ZEB2 2.367
8 LZTS1 2.221
9 GPM6B 2.174
10 TYR 2.038
11 PHACTR1 1.928
12 FBXL7 1.875
13 DCT 1.873
14 RHOJ 1.842
15 ALX1 1.827
16 FCRLA 1.821
17 CAPN3 1.746
18 DAAM2 1.709
19 GAS7 1.707
20 SNCA 1.688
Open in a new tab

Filtering was performed for the medical subject heading term ‘Melanoma’ and the score for each gene is the summation of edge-weights (Log likelihood score) to all connected genes in Coexpedia analysis.

Figure 4.

Figure 4.

Open in a new tab

Filtered network for the medical subject heading term ‘Melanoma’. This was obtained by Coexpedia analysis. The score for each gene is the summation of edge-weights (Log likelihood score) to all connected genes in the network. The thicker the line the closer the association with PAX3. SOX10 ranked highest with a score of 2.778 (shown in yellow frame). PAX3, paired box 3; SOX10, SRY-box 10.

Table II.

Co-expression analysis of PAX3 using Oncomine.

Gene Correlation Reporter ID
PAX3 1.000 216059_at
SOX10 0.806 209842_at
TYR 0.806 206630_at
EDNRB 0.806 204273_at
TNFRSF14 0.806 209354_at
SOX5 0.806 207336_at
SNCA 0.806 207827_x_at
SLC45A2 0.806 220245_at
SLC45A2 0.806 221644_s_at
SNCA 0.806 211546_x_at
AP1S2 0.806 203299_s_at
AP1S2 0.806 203300_x_at
LZTS1 0.806 219042_at
MLANA 0.806 206426_at
MITF 0.806 207233_s_at
SRPX 0.806 204955_at
BNC2 0.806 220272_at
SNCA 0.806 204466_s_at
MLANA 0.806 206427_s_at
EDNRB 0.806 204271_s_at
Open in a new tab

The correlation (log2 median-centered intensity) in the table represents genes co-expressed with PAX3 in the Pratilas cell line (23) (GSE10087) derived from melanoma in Oncomine analysis.

Figure 5.

Figure 5.

Open in a new tab

According to Oncomine analysis, PAX3 expression is significantly associated with SOX10 expression (shown in red frame). The cancer cell lines were derived from different tumors. PAX3, paired box 3; SOX10, SRY-box 10.

Figure 6.

Figure 6.

Open in a new tab

SOX10 mRNA expression in different tumor cells according to Cancer Cell Line Encyclopedia analysis. The mRNA expression level of SOX10 was ranked highest in melanoma cell lines (shown in green frame). The numbers in parentheses indicate the sample size and the y-axis indicates mRNA expression (RNAseq). PAX3, paired box 3; SOX10, SRY-box 10; AML, acute myeloid leukemia; B-cell_ALL, B-cell acute lymphocytic leukemia; CML, chronic myeloid leukemia; Lung_NSC, non-small-cell lung cancer; Lymphoma_DLBCL, diffuse large B-cell lymphoma; NA, nasopharyngeal carcinoma; RNAseq, RNA sequencing; T-cell_ALL, T-cell acute lymphocytic leukemia.

Figure 7.

Figure 7.

Open in a new tab

Cancer Cell Line Encyclopedia analysis reveals that SOX10 is overexpressed in melanoma cell lines with high expression levels of PAX3, but is downregulated in those with low PAX3 expression. PAX3, paired box 3; SOX10, SRY-box 10.

PAX3 predicts a worse survival rate in patients with melanoma

In a study by Xu et al (24), the overall survival rate was statistically analyzed using the Kaplan-Meier method and a log-rank test was used to compare high and low expression groups. In the present study the median of all sample expression values was calculated. The cut-off value was −0.921135. If the sample expression value was less than the median, it was considered to belong to the low expression group, otherwise it was considered to belong to the high expression group. Low mRNA expression levels of PAX3 were associated with a significantly longer survival time in all patients with melanoma [hazard ratio (HR)=2.274, P=0.0086; Fig. 8A]. High mRNA expression levels of PAX3 were significantly associated with shorter survival time (HR=2.454, P=0.0252; Fig. 8B). Low mRNA expression levels of PAX3 were significantly associated with longer survival time in patients with superficial spreading melanoma (HR=2.454, P=0.0252; Fig. 8B). Low mRNA expression of PAX3 was not significantly associated with longer survival time in nodular melanoma (HR=3.262, P=0.0792) (Fig. 8C). In addition, compared with female patients with melanoma, male patients with melanoma exhibited higher PAX3 expression (P=0.0286, t=2.232; Fig. 8D). These results suggested that PAX3 may serve a unique role in the development of melanoma.

Figure 8.

Figure 8.

Open in a new tab

Prognostic value of PAX3 mRNA expression in melanoma. (A) High mRNA expression levels of PAX3 were associated with a shorter survival time in all patients with melanoma. (B) High mRNA expression levels of PAX3 were associated with a shorter survival time in patients with superficial spreading melanoma. (C) High mRNA expression levels of PAX3 were associated with a shorter survival time in patients with nodular melanoma. (D) Comparison of PAX3 mRNA expression in males and females. PAX3, paired box 3.

Discussion

During previous years, the understanding of melanoma development and biology has improved. It has become clear that the progression from premalignant lesions to fully developed melanoma does not represent a single evolutionary pattern. Each melanoma subtype can develop from different precursor lesions and may exhibit different stages of gene mutation and transformation (25). However, some patients relapse with disseminated disease, and ~10% of melanoma cases are diagnosed during late stages and are either unresectable or have metastasized (26). Therefore, a number of studies have investigated the development of melanoma to improve targeted therapies (26–28).

PAX3 serves a vital regulatory role in pigment cell development during embryonic development (29). Medic et al (9) suggested that there is no statistically significant difference in the expression of PAX3 in melanocytes and melanoma cells; however, Bailey et al (30) demonstrated that PAX3 expression is significantly inhibited in adult melanocytes and the expression of PAX3 mRNA in melanoma cells is 200-times that of normal skin (31). Notably, PAX3, particularly PAX3E, significantly inhibits the proliferation and increases chemosensitivity of melanoma cells (15,32–35), meanwhile, treatment with PAX3 inhibitors resulted in a significant decrease in PAX3 expression in melanoma cells, whereas PAX3 expression had no change in melanocytes (36). PAX3 may not only drive the expression of genes that promote cellular metastasis and invasion, but may also regulate the mRNA expression levels of genes involved in melanoma differentiation, proliferation and survival (9,34,37). Reid et al (14) revealed that PAX3 expression is evident at all stages of melanoma progression, including primary lesions, circulating melanoma cells and metastatic lesions. Medic et al (9) suggested that PAX3 directly targets the transforming growth factor β1 promoter in metastatic melanoma cell lines, as well as other genes associated with cell migration, including melanoma cell adhesion molecule, chondroitin sulfate proteoglycan 4 and CXCR4. Additionally, PAX3 may drive CXCR4 expression to promote melanoma metastasis (18). In addition, silencing PAX3 with RNA interference can inhibit proliferation and induce terminal differentiation and apoptosis, according to the activation of caspase-3 and p53 in melanoma cells (38–40). Notably, >2.76 copies/µl of PAX3d mRNA in the bloodstream predicts recurrence of cutaneous malignant melanoma (41). Furthermore, the human PAX3 gene may serve a role in other human malignancies, including rhabdomyosarcoma and Ewing's sarcoma (42). Co-expression analysis using Oncomine revealed a positive association between PAX3 expression and SOX10 expression. The findings of Bondurand et al (43) are consistent with the complex functional roles of PAX3 and SOX10 in neural crest stem cell-derived melanocyte development, and SOX10 has been demonstrated to markedly activate melanocyte inducing transcription factor (MITF) expression in cultured cell lines, while PAX3 synergistically transactivates the promoter of MITF with SOX10 to influence the maintenance of melanocyte stem cells (43–45). Additionally, a small number of PAX3 transcriptional cofactors have been identified, but only SOX10 and ETS proto-oncogene 1 transcription factor have been verified within melanoma cells (46). Furthermore, there is increasing evidence that signaling proteins tend to form interaction networks rather than simple linear pathways, meaning PAX3 and SOX10 may use specific interaction networks to regulate the proliferation, differentiation and migration of melanocyte precursors (47–51).

In the present study, the incidence rate of melanoma was identified to be higher in men than in women. Using Oncomine analysis, the expression of PAX3 in male patients with melanoma was significantly higher than in female patients (P=0.0286, t=2.232). Some studies have suggested that this increased male susceptibility may be associated with androgens (52–54) and hyperandrogenism may result in variants in melanoma-associated pigmentary genes (55–58). According to Kocarnik et al (59), the solute carrier family 45 member 2 single nucleotide polymorphism rs16891982, which has a non-synonymous mutation (F374L) located in exon 5, may be responsible for imparting a higher melanoma risk in men, possibly through alterations in pigmentation and melanogenesis (60). Therefore, the present study demonstrated that the differential expression of PAX3 and its downstream targets may be a potential predictor of sex-specific genetic risks in melanoma.

In conclusion, PAX3 was highly expressed in melanoma and predicted a worse survival rate for patients with melanoma. PAX3 expression was positively associated with SOX10 expression, and the expression of PAX3 in male patients with melanoma was significantly higher than that in female patients. The aforementioned evidence indicated that PAX3 may act as a potential modulator in melanoma.

Acknowledgements

The authors would like to thank Dr H. Nikki March, for editing the English text of a draft of this manuscript.

Funding

This study was partly supported by the National Natural Science Foundation of China (grant no. 81704087), the National Disease Research Program of TCM (grant no. 20160524), the Innovative Talents Promotion Project-Key Scientific and Technological Innovation Team Project (grant no. 2017KCT-27) and the Shaanxi Province Clinical Medical Research Center Project (grant no. 2016LCZX-12).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

YL and SC designed the study and drafted the manuscript. WL and YZ were primarily dedicated to collecting and statistically analyzing data. XY and JX supervised the scientific work, interpreted the data, revised the manuscript, provided financial support and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

  • 1.Little EG, Eide MJ. Update on the current state of melanoma incidence. Dermatol Clin. 2012;30:355–361. doi: 10.1016/j.det.2012.04.001. [DOI] [PubMed] [Google Scholar]
  • 2.Buzaid AC, Atkins M. Practical guidelines for the management of biochemotherapy-related toxicity in melanoma. Clin Cancer Res. 2001;7:2611–2619. [PubMed] [Google Scholar]
  • 3.Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96. doi: 10.3322/CA.2007.0010. [DOI] [PubMed] [Google Scholar]
  • 4.Robson EJ, He SJ, Eccles MR. A PANorama of PAX genes in cancer and development. Nat Rev Cancer. 2006;6:52–62. doi: 10.1038/nrc1778. [DOI] [PubMed] [Google Scholar]
  • 5.Corry GN, Underhill DA. Pax3 target gene recognition occurs through distinct modes that are differentially affected by disease-associated mutations. Pigment Cell Res. 2005;18:427–38. doi: 10.1111/j.1600-0749.2005.00275.x. [DOI] [PubMed] [Google Scholar]
  • 6.Chalepakis G, Gruss P. Identification of DNA recognition sequences for the Pax3 paired domain. Gene. 1995;162:267–270. doi: 10.1016/0378-1119(95)00345-7. [DOI] [PubMed] [Google Scholar]
  • 7.Chalepakis G, Jones FS, Edelman GM, Gruss P. Pax-3 contains domains for transcription activation and transcription inhibition. Proc Natl Acad Sci USA. 1994;91:12745–12749. doi: 10.1073/pnas.91.26.12745. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Epstein DJ, Vogan KJ, Trasler DG, Gros P. A mutation within intron 3 of the Pax-3 gene produces aberrantly spliced mRNA transcripts in the splotch (Sp) mouse mutant. Proc Natl Acad Sci USA. 1993;90:532–536. doi: 10.1073/pnas.90.2.532. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Medic S, Rizos H, Ziman M. Differential PAX3 functions in normal skin melanocytes and melanoma cells. Biochem Biophys Res Commun. 2011;411:832–837. doi: 10.1016/j.bbrc.2011.07.053. [DOI] [PubMed] [Google Scholar]
  • 10.Barber TD, Barber MC, Cloutier TE, Friedman TB. PAX3 gene structure, alternative splicing and evolution. Gene. 1999;237:311–319. doi: 10.1016/S0378-1119(99)00339-X. [DOI] [PubMed] [Google Scholar]
  • 11.Barr FG, Fitzgerald JC, Ginsberg JP, Vanella ML, Davis RJ, Bennicelli JL. Predominant expression of alternative PAX3 and PAX7 forms in myogenic and neural tumor cell lines. Cancer Res. 1999;59:5443–5448. [PubMed] [Google Scholar]
  • 12.Takeuchi H, Morton DL, Kuo C, Turner RR, Elashoff D, Elashoff R, Taback B, Fujimoto A, Hoon DS. Prognostic significance of molecular upstaging of paraffin embedded sentinel lymph nodes in melanoma patients. J Clin Oncol. 2004;22:2671–2680. doi: 10.1200/JCO.2004.12.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Galibert MD, Yavuzer U, Dexter TJ, Goding CR. Pax3 and regulation of the melanocyte-specific tyrosinase-related protein-1 promoter. J Biol Chem. 1999;274:26894–26900. doi: 10.1074/jbc.274.38.26894. [DOI] [PubMed] [Google Scholar]
  • 14.Reid AL, Millward M, Pearce R, Lee M, Frank MH, Ireland A, Monshizadeh L, Rai T, Heenan P, Medic S, et al. Markers of circulating tumour cells in the peripheral blood of patients with melanoma correlate with disease recurrence and progression. Br J Dermatol. 2013;168:85–92. doi: 10.1111/bjd.12057. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Kubic JD, Little EC, Lui JW, Iizuka T, Lang D. PAX3 and ETS1 synergistically activate MET expression in melanoma cells. Oncogene. 2015;34:4964–4974. doi: 10.1038/onc.2014.420. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Kubic JD, Lui JW, Little EC, Ludvik AE, Konda S, Salgia R, Aplin AE, Lang D. PAX3 and FOXD3 promote CXCR4 expression in melanoma. J Biol Chem. 2015;290:21901–21914. doi: 10.1074/jbc.M115.670976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Cao J, Dai X, Wan L, Wang H, Zhang J, Goff PS, Sviderskaya EV, Xuan Z, Xu Z, Xu X, et al. The E3 ligase APC/C(Cdh1) promotes ubiquitylation-mediated proteolysis of PAX3 to suppress melanocyte proliferation and melanoma growth. Sci Signal. 2015;8:ra87. doi: 10.1126/scisignal.aab1995. [DOI] [PubMed] [Google Scholar]
  • 18.Iyengar AS, Miller PJ, Loupe JM, Hollenbach AD. Phosphorylation of PAX3 contributes to melanoma phenotypes by affecting proliferation, invasion, and transformation. Pigment Cell Melanoma Res. 2014;27:846–848. doi: 10.1111/pcmr.12277. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Haqq C, Nosrati M, Sudilovsky D, Crothers J, Khodabakhsh D, Pulliam BL, Federman S, Miller JR, III, Allen RE, Singer MI, et al. The gene expression signatures of melanoma progression. Proc Natl Acad Sci USA. 2005;102:6092–6097. doi: 10.1073/pnas.0501564102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Riker AI, Enkemann SA, Fodstad O, Liu S, Ren S, Morris C, Xi Y, Howell P, Metge B, Samant RS, et al. The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med Genomics. 2008;1:13. doi: 10.1186/1755-8794-1-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Talantov D, Mazumder A, Yu JX, Briggs T, Jiang Y, Backus J, Atkins D, Wang Y. Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin Cancer Res. 2005;11:7234–7242. doi: 10.1158/1078-0432.CCR-05-0683. [DOI] [PubMed] [Google Scholar]
  • 22.Wagner KW, Punnoose EA, Januario T, Lawrence DA, Pitti RM, Lancaster K, Lee D, von Goetz M, Yee SF, Totpal K, et al. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med. 2007;13:1070–1077. doi: 10.1038/nm1627. [DOI] [PubMed] [Google Scholar]
  • 23.Pratilas CA, Taylor BS, Ye Q, Viale A, Sander C, Solit DB, Rosen N. (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci USA. 2009;106:4519–4524. doi: 10.1073/pnas.0900780106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Xu L, Shen SS, Hoshida Y, Subramanian A, Ross K, Brunet JP, Wagner SN, Ramaswamy S, Mesirov JP, Hynes RO. Gene expression changes in an animal melanoma model correlate with aggressiveness of human melanoma metastases. Mol Cancer Res. 2008;6:760–769. doi: 10.1158/1541-7786.MCR-07-0344. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Shain AH, Bastian BC. From melanocytes to melanomas. Nat Rev Cancer. 2016;16:345–358. doi: 10.1038/nrc.2016.37. [DOI] [PubMed] [Google Scholar]
  • 26.Luke JJ, Flaherty KT, Ribas A, Long GV. Targeted agents and immunotherapies: Optimizing outcomes in melanoma. Nat Rev Clin Oncol. 2017;14:463–482. doi: 10.1038/nrclinonc.2017.43. [DOI] [PubMed] [Google Scholar]
  • 27.Amann VC, Ramelyte E, Thurneysen S, Pitocco R, Bentele-Jaberg N, Goldinger SM, Dummer R, Mangana J. Developments in targeted therapy in melanoma. Eur J Surg Oncol. 2017;43:581–593. doi: 10.1016/j.ejso.2016.10.014. [DOI] [PubMed] [Google Scholar]
  • 28.Christiansen SA, Khan S, Gibney GT. Targeted therapies in combination with immune therapies for the treatment of metastatic melanoma. Cancer J. 2017;23:59–62. doi: 10.1097/PPO.0000000000000245. [DOI] [PubMed] [Google Scholar]
  • 29.Lang D, Lu MM, Huang L, Engleka KA, Zhang M, Chu EY, Lipner S, Skoultchi A, Millar SE, Epstein JA. Pax3 functions at a nodal point in melanocyte stem cell differentiation. Nature. 2005;433:884–887. doi: 10.1038/nature03292. [DOI] [PubMed] [Google Scholar]
  • 30.Bailey CM, Morrison JA, Kulesa PM. Melanoma revives an embryonic migration program to promote plasticity and invasion. Pigment Cell Melanoma Res. 2012;25:573–583. doi: 10.1111/j.1755-148X.2012.01025.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Medic S, Ziman M. PAX3 expression in normal skin melanocytes and melanocytic lesions (naevi and melanomas) PLoS One. 2010;5:e9977. doi: 10.1371/journal.pone.0009977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Hathaway-Schrader JD, Doonan BP, Hossain A, Radwan FFY, Zhang L, Haque A. Autophagy-dependent crosstalk between GILT and PAX-3 influences radiation sensitivity of human melanoma cells. J Cell Biochem. 2018;119:2212–2221. doi: 10.1002/jcb.26383. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Wang Q, Kumar S, Slevin M, Kumar P. Functional analysis of alternative isoforms of the transcription factor PAX3 in melanocytes in vitro. Cancer Res. 2006;66:8574–8580. doi: 10.1158/0008-5472.CAN-06-0947. [DOI] [PubMed] [Google Scholar]
  • 34.Liu F, Cao J, Lv J, Dong L, Pier E, Xu GX, Wang RA, Xu Z, Goding C, Cui R. TBX2 expression is regulated by PAX3 in the melanocyte lineage. Pigment Cell Melanoma Res. 2013;26:67–77. doi: 10.1111/pcmr.12029. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Liu F, Cao J, Wu J, Sullivan K, Shen J, Ryu B, Xu Z, Wei W, Cui R. Stat3-targeted therapies overcome the acquired resistance to vemurafenib in melanomas. J Invest Dermatol. 2013;133:2041–2049. doi: 10.1038/jid.2013.32. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Smith MP, Ferguson J, Arozarena I, Hayward R, Marais R, Chapman A, Hurlstone A, Wellbrock C. Effect of SMURF2 targeting on susceptibility to MEK inhibitors in melanoma. J Natl Cancer Inst. 2013;105:33–46. doi: 10.1093/jnci/djs471. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Bartlett D, Boyle GM, Ziman M, Medic S. Mechanisms contributing to differential regulation of PAX3 downstream target genes in normal human epidermal melanocytes versus melanoma cells. PLoS One. 2015;10:e0124154. doi: 10.1371/journal.pone.0124154. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.He S, Li CG, Slobbe L, Glover A, Marshall E, Baguley BC, Eccles MR. PAX3 knockdown in metastatic melanoma cell lines does not reduce MITF expression. Melanoma Res. 2011;21:24–34. doi: 10.1097/CMR.0b013e328341c7e0. [DOI] [PubMed] [Google Scholar]
  • 39.He SJ, Stevens G, Braithwaite AW, Eccles MR. Transfection of melanoma cells with antisense PAX3 oligonucleotides additively complements cisplatin-induced cytotoxicity. Mol Cancer Ther. 2005;4:996–1003. doi: 10.1158/1535-7163.MCT-04-0252. [DOI] [PubMed] [Google Scholar]
  • 40.Scholl FA, Kamarashev J, Murmann OV, Geertsen R, Dummer R, Schäfer BW. PAX3 is expressed in human melanomas and contributes to tumor cell survival. Cancer Res. 2001;61:823–826. [PubMed] [Google Scholar]
  • 41.Autilio C, Paolillo C, Lavieri MM, Pocino K, De Paolis E, Di Stasio E, Marchetti P, Gian Carlo CA, Capoluongo E. PAX3d mRNA over 2.76 copies/µl in the bloodstream predicts cutaneous malignant melanoma relapse. Oncotarget. 2017;8:85479–85491. doi: 10.18632/oncotarget.20177. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Wang Q, Fang WH, Krupinski J, Kumar S, Slevin M, Kumar P. Pax genes in embryogenesis and oncogenesis. J Cell Mol Med. 2008;12:2281–2294. doi: 10.1111/j.1582-4934.2008.00427.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Bondurand N, Pingault V, Goerich DE, Lemort N, Sock E, Le Caignec C, Wegner M, Goossens M. Interaction among SOX10, PAX3 and MITF, three genes altered in Waardenburg syndrome. Hum Mol Genet. 2000;9:1907–1917. doi: 10.1093/hmg/9.13.1907. [DOI] [PubMed] [Google Scholar]
  • 44.Potterf SB, Furumura M, Dunn KJ, Arnheiter H, Pavan WJ. Transcription factor hierarchy in Waardenburg syndrome: Regulation of MITF expression by SOX10 and PAX3. Hum Genet. 2000;107:1–6. doi: 10.1007/s004390000328. [DOI] [PubMed] [Google Scholar]
  • 45.Watanabe A, Takeda K, Ploplis B, Tachibana M. Epistatic relationship between Waardenburg syndrome genes MITF and PAX3. Nat Genet. 1998;18:283–286. doi: 10.1038/ng0398-283. [DOI] [PubMed] [Google Scholar]
  • 46.Mascarenhas JB, Littlejohn EL, Wolsky RJ, Young KP, Nelson M, Salgia R, Lang D. PAX3 and SOX10 activate MET receptor expression in melanoma. Pigment Cell Melanoma Res. 2010;23:225–237. doi: 10.1111/j.1755-148X.2010.00667.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Hou L, Pavan WJ. Transcriptional and signaling regulation in neural crest stem cell-derived melanocyte development: Do all roads lead to Mitf? Cell Res. 2008;18:1163–1176. doi: 10.1038/cr.2008.303. [DOI] [PubMed] [Google Scholar]
  • 48.Otręba M, Miliński M, Buszman E, Wrześniok D, Beberok A. Hereditary hypomelanocytoses: The role of PAX3, SOX10, MITF, SNAI2, KIT, EDN3 and EDNRB genes. Postepy Hig Med Dosw (Online) 2013;67:1109–1118. doi: 10.5604/17322693.1077722. (In Polish) [DOI] [PubMed] [Google Scholar]
  • 49.Pingault V, Ente D, Dastot-Le Moal F, Goossens M, Marlin S, Bondurand N. Review and update of mutations causing Waardenburg syndrome. Hum Mutat. 2010;31:391–406. doi: 10.1002/humu.21211. [DOI] [PubMed] [Google Scholar]
  • 50.Otręba M, Rok J, Buszman E, Wrześniok D. Regulation of melanogenesis: The role of cAMP and MITF. Postepy Hig Med Dosw (Online) 2012;66:33–40. (In Polish) [PubMed] [Google Scholar]
  • 51.Lin JY, Fisher DE. Melanocyte biology and skin pigmentation. Nature. 2007;445:843–850. doi: 10.1038/nature05660. [DOI] [PubMed] [Google Scholar]
  • 52.Li WQ, Cho E, Weinstock MA, Mashfiq H, Qureshi AA. Epidemiological assessments of skin outcomes in the nurses' health studies. Am J Public Health. 2016;106:1677–1683. doi: 10.2105/AJPH.2016.303315. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Zhang M, Qureshi AA, Geller AC, Frazier L, Hunter DJ, Han J. Use of tanning beds and incidence of skin cancer. J Clin Oncol. 2012;30:1588–1593. doi: 10.1200/JCO.2011.39.3652. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Li WQ, Qureshi AA, Ma J, Goldstein AM, Giovannucci EL, Stampfer MJ, Han J. Personal history of prostate cancer and increased risk of incident melanoma in the United States. J Clin Oncol. 2013;31:4394–4399. doi: 10.1200/JCO.2013.51.1915. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Nair-Shalliker V, Egger S, Chrzanowska A, Mason R, Waite L, Le Couteur D, Seibel MJ, Handelsman DJ, Cumming R, Smith DP, Armstrong BK. Associations between sun sensitive pigmentary genes and serum prostate specific antigen levels. PLoS One. 2018;13:e0193893. doi: 10.1371/journal.pone.0193893. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Chia SE, Wong KY, Cheng C, Lau W, Tan PH. Sun exposure and the risk of prostate cancer in the singapore prostate cancer study: A case-control study. Asian Pac J Cancer Prev. 2012;13:3179–3185. doi: 10.7314/APJCP.2012.13.7.3179. [DOI] [PubMed] [Google Scholar]
  • 57.Nair-Shalliker V, Smith DP, Egger S, Hughes AM, Kaldor JM, Clements M, Kricker A, Armstrong BK. Sun exposure may increase risk of prostate cancer in the high UV environment of New South Wales, Australia: A case-control study. Int J Cancer. 2012;131:E726–E732. doi: 10.1002/ijc.27400. [DOI] [PubMed] [Google Scholar]
  • 58.Bonilla C, Gilbert R, Kemp JP, Timpson NJ, Evans DM, Donovan JL, Hamdy FC, Neal DE, Fraser WD, Davey SG, et al. Using genetic proxies for lifecourse sun exposure to assess the causal relationship of sun exposure with circulating vitamin d and prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 2013;22:597–606. doi: 10.1158/1055-9965.EPI-12-1248. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Kocarnik JM, Park SL, Han J, Dumitrescu L, Cheng I, Wilkens LR, Schumacher FR, Kolonel L, Carlson CS, Crawford DC, et al. Replication of associations between GWAS SNPs and melanoma risk in the Population Architecture Using Genomics and Epidemiology (PAGE) Study. J Invest Dermatol. 2014;134:2049–2052. doi: 10.1038/jid.2014.53. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Hernando B, Ibarrola-Villava M, Fernandez LP, Peña-Chilet M, Llorca-Cardeñosa M, Oltra SS, Alonso S, Boyano MD, Martinez-Cadenas C, Ribas G. Sex-specific genetic effects associated with pigmentation, sensitivity to sunlight, and melanoma in a population of Spanish origin. Biol Sex Differ. 2016;7:17. doi: 10.1186/s13293-016-0070-1. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Articles from Oncology Letters are provided here courtesy of Spandidos Publications

RESOURCES